Advertisement
Screener

ACLARION, INC. (ACON) Income (Loss) from Continuing Operations before Income Taxes, Domestic

1.8 / 5 stars · 16/44 Roast Me

ACLARION, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic

ACLARION, INC. (ACON) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$3.71 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.

Discontinued › Income Statement

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2022-08-15

  • ACLARION, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2022-06-30 was -$3.71M.
  • ACLARION, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2022-03-31 was -$936.09K.
  • ACLARION, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-06-30 was -$465.84K.
  • ACLARION, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-03-31 was -$517.86K.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Domestic 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 6 month
2022-06-30-$3.71M
10-Q · filed 2022-08-15
-$4.64M
10-Q · filed 2022-08-15
2022-03-31-$936.09K
10-Q · filed 2022-06-06
2021-06-30-$465.84K
10-Q · filed 2022-08-15
-$983.70K
10-Q · filed 2022-08-15
2021-03-31-$517.86K
10-Q · filed 2022-06-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Advanced Biomed Inc. (ADVB)$0.009B
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
BioNexus Gene Lab Corp (BGLC)$0.004B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45